Masimo (MASI) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
27 Feb, 2026Capital allocation and financing
On December 1, 2025, a new unsecured credit agreement was executed, providing a $250M term loan and a $750M revolving credit facility, with an accordion feature for up to $400M in additional commitments, maturing December 1, 2030.
The agreement includes Bank of America as administrative agent, with several major banks as joint lead arrangers and lenders.
The facility allows for both ABR and Term SOFR loans, with interest rates and unused fees determined by a leverage-based pricing grid.
The agreement contains customary affirmative and negative covenants, including financial covenants: a maximum total net leverage ratio of 3.5x (step-up to 4.0x for certain material investments) and a minimum interest coverage ratio of 3.0x.
The facility includes provisions for letters of credit, cash collateralization, and lender replacement in the event of default or other specified circumstances.
Key financial ratios and metrics
Total net leverage ratio must not exceed 3.5x, with a temporary increase to 4.0x following a material investment, reverting after three quarters.
Interest coverage ratio must be at least 3.0x, calculated on a trailing four-quarter basis.
The agreement defines EBITDA and net leverage in detail, including permitted add-backs and exclusions.
Significant events and developments
The new credit agreement replaces the prior 2022 facility and was executed in connection with the company’s ongoing capital structure management.
The agreement supports general corporate purposes, including permitted acquisitions and share repurchases.
The agreement includes a comprehensive set of representations, warranties, and events of default, including cross-defaults, change of control, and material adverse effect clauses.
Latest events from Masimo
- Merger with Danaher and executive compensation proposals approved by shareholders.MASI
EGM 2026 - Shareholders to vote on $180 per share Danaher merger, with board support and litigation addressed.MASI
Proxy filing - Shareholders to vote on $180/share all-cash merger with Danaher and related executive compensation.MASI
Proxy filing - Stockholders to vote on $180/share Danaher acquisition, with board unanimous support and premium offered.MASI
Proxy Filing - Masimo to be acquired by Danaher for $180 per share, pending shareholder approval.MASI
Proxy Filing - Board approves $180/share Danaher acquisition; shareholder vote and regulatory review pending.MASI
Proxy Filing - Shareholders will vote on a $180/share all-cash merger, with closing expected in late 2026.MASI
Proxy Filing - Q3 revenue up 5% to $504.6M, with healthcare growth and raised EPS guidance for 2024.MASI
Q3 2024 - Q4 and 2024 saw strong revenue and margin growth, with 8–11% healthcare growth expected in 2025.MASI
Q4 2024